JP2025102775A5 - - Google Patents
Info
- Publication number
- JP2025102775A5 JP2025102775A5 JP2025034340A JP2025034340A JP2025102775A5 JP 2025102775 A5 JP2025102775 A5 JP 2025102775A5 JP 2025034340 A JP2025034340 A JP 2025034340A JP 2025034340 A JP2025034340 A JP 2025034340A JP 2025102775 A5 JP2025102775 A5 JP 2025102775A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical combination
- administering
- antibody
- dexamethasone
- lenalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809070P | 2019-02-22 | 2019-02-22 | |
| US62/809,070 | 2019-02-22 | ||
| US201962829814P | 2019-04-05 | 2019-04-05 | |
| US201962829791P | 2019-04-05 | 2019-04-05 | |
| US201962829804P | 2019-04-05 | 2019-04-05 | |
| US62/829,791 | 2019-04-05 | ||
| US62/829,804 | 2019-04-05 | ||
| US62/829,814 | 2019-04-05 | ||
| JP2021549416A JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
| PCT/IB2020/051484 WO2020170211A1 (en) | 2019-02-22 | 2020-02-21 | Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Division JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025102775A JP2025102775A (ja) | 2025-07-08 |
| JP2025102775A5 true JP2025102775A5 (https=) | 2026-01-09 |
Family
ID=72141407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Active JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
| JP2025034340A Pending JP2025102775A (ja) | 2019-02-22 | 2025-03-05 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021549416A Active JP7721445B2 (ja) | 2019-02-22 | 2020-02-21 | Ｃｄ３８に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200268847A1 (https=) |
| EP (1) | EP3927376A4 (https=) |
| JP (2) | JP7721445B2 (https=) |
| CN (1) | CN113727729A (https=) |
| CA (1) | CA3131064A1 (https=) |
| WO (1) | WO2020170211A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| AU2015358615B2 (en) | 2014-12-04 | 2021-08-05 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute myeloid leukemia |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| DK3827845T3 (da) | 2015-11-03 | 2022-05-23 | Janssen Biotech Inc | Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf |
| JP2019527678A (ja) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療 |
| JP2021502961A (ja) | 2017-10-31 | 2021-02-04 | ヤンセン バイオテツク，インコーポレーテツド | 高リスク多発性骨髄腫の治療方法 |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3834889A1 (en) * | 2014-06-16 | 2021-06-16 | Mayo Foundation for Medical Education and Research | Treating myelomas |
| US10617757B2 (en) * | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| US20170044265A1 (en) * | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
-
2020
- 2020-02-21 CN CN202080015963.2A patent/CN113727729A/zh active Pending
- 2020-02-21 WO PCT/IB2020/051484 patent/WO2020170211A1/en not_active Ceased
- 2020-02-21 JP JP2021549416A patent/JP7721445B2/ja active Active
- 2020-02-21 EP EP20759735.2A patent/EP3927376A4/en active Pending
- 2020-02-21 US US16/797,301 patent/US20200268847A1/en active Pending
- 2020-02-21 CA CA3131064A patent/CA3131064A1/en active Pending
-
2025
- 2025-03-05 JP JP2025034340A patent/JP2025102775A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025102775A5 (https=) | ||
| US12435138B2 (en) | Immunotoxins, formulations thereof and their use in medicine | |
| JP6278224B2 (ja) | Ｐｄ−１アゴニストからなる自己免疫疾患治療剤 | |
| CN103533943B (zh) | 由cd3特异性结合结构域导致的不良作用的预防 | |
| JP2025011257A (ja) | Ｉｌ－４ｒ阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法 | |
| JP2022002524A5 (https=) | ||
| TWI890481B (zh) | 雙特異性抗體 | |
| JP2011504872A5 (https=) | ||
| CN114173819A (zh) | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 | |
| CA2842195A1 (en) | Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death | |
| JP7783183B2 (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| JP2024161505A (ja) | Ｈｌａ感作患者を脱感作し患者における腎移植を改善するためのクラザキズマブの使用 | |
| Holle et al. | ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy | |
| US20240409656A1 (en) | Methods of treating cd20 expressing b-cell cancers | |
| JPWO2020170211A5 (https=) | ||
| JP2021505545A (ja) | 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法 | |
| KR20230107115A (ko) | 항-icam-1 항체의 단기요법을 이용한 간이식 거부반응의 억제방법 | |
| CN116635422A (zh) | 抗cd38抗体及其用途 | |
| TW202019482A (zh) | Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法 | |
| US20250304689A1 (en) | Bispecific antibodies against cd3 and cd20 | |
| Lee et al. | High-Dose Intravenous Immunoglobulin to Treat Anti-Thymocyte Globulin Induction–Related BK Virus and Cytomegalovirus Infection in Patients with ABO-Incompatible Kidney Transplantation | |
| Nachman et al. | Developments in the immunotherapy of glomerular disease | |
| Kedar et al. | The role of intravenous immunoglobulins in the management of acute complex autoimmune conditions | |
| Reichenbach | A Sight for Sorre (l’s) Eyes | |
| Spearman et al. | Immune tolerance and immunosuppression in solid organ transplantation |